OTCMKTS:SPHS

Sophiris Bio (SPHS) Stock Price, News & Analysis

Sophiris Bio logo

About Sophiris Bio Stock (OTCMKTS:SPHS)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
$4 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Sophiris Bio, Inc. was a biotechnology company focused on developing locally administered therapies for urological diseases. The company’s research centered on treatments intended to address conditions affecting the prostate while limiting exposure to healthy tissue.

Sophiris’ primary product candidate was topsalysin, also known as PRX302, a recombinant protein therapy designed to be activated within prostate tissue. The company investigated topsalysin as a potential treatment for benign prostatic hyperplasia, a common condition that can cause urinary symptoms, and for localized prostate cancer.

The company was formerly known as Protox Therapeutics and adopted the Sophiris Bio name as it advanced its urology-focused development programs. Publicly available information about its later operations, leadership, geographic activities and commercial status is limited, and the company’s programs were primarily associated with clinical-stage research rather than marketed products.

AI Generated. May Contain Errors.

Receive SPHS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sophiris Bio and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SPHS Stock News Headlines

Sophiris Bio Inc Stock Price History
Sophiris Bio Inc (SPHS)
Your $7 scanner is waiting
The Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which stock, what price, and when to exit. The list reads the same whether you've traded for twenty years or twenty days, and it doesn't depend on account size. If it's not for you, refund the $7 and still keep the scanner for the full year. One payment, no re-bills.tc pixel
Best Louisiana High Schools
BLTE - Belite Bio, Inc
Bio-Reference Laboratories
Sophiris Bio Inc. Registered Sh (BFF1.SG)
See More Headlines

SPHS Stock Analysis - Frequently Asked Questions

Sophiris Bio, Inc. (OTCMKTS:SPHS) released its earnings results on Thursday, May, 9th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.02.

Based on aggregate information from My MarketBeat watchlists, some other companies that Sophiris Bio investors own include Advanced Micro Devices (AMD), Aurinia Pharmaceuticals (AUPH), Novavax (NVAX), Sarepta Therapeutics (SRPT), GE Aerospace (GE), Anavex Life Sciences (AVXL) and Eyepoint Pharmaceuticals (EYPT).

Company Calendar

Today
11/17/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
OTCMKTS:SPHS
CIK
1563855
Fax
N/A
Employees
6
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
35,550,000
Free Float
N/A
Market Cap
$4 thousand
Optionable
Not Optionable
Beta
1.94
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

This page (OTCMKTS:SPHS) was last updated on 4/11/2022 by MarketBeat.com Staff.
From Our Partners